Larimar Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
Larimar Therapeutics, Inc. (LRMR) filed this Current Report on Form 8-K on January 12, 2026. The filing discloses preliminary financial information as of December 31, 2025, based on an updated corporate presentation posted to the company's website.
Key Financial Metrics
- Cash and Liquidity: As of December 31, 2025, the Company reported approximately $136.9 million in cash, cash equivalents, and marketable securities.
- Revenue, Profit, and Margins: The filing text does not provide specific values for revenue, net income, operating margins, or cash flow for the period.
- Debt: The filing text does not provide specific values for outstanding debt.
Material Changes and Data Status
The reported cash balance of $136.9 million is unaudited and preliminary. The Company has not yet completed its quarter-end or year-end financial close processes for the period ended December 31, 2025. Consequently, the actual results may differ materially from this estimate once the financial closing procedures are finalized.
Outlook, Risks, and Management Commentary
Management notes that the preliminary data is subject to change upon completion of financial closing procedures. The Company's independent registered public accounting firm, PricewaterhouseCoopers LLP, has not audited, reviewed, or performed any procedures on this data and expresses no assurance regarding it. The final audited results for the year ended December 31, 2025, will be included in the upcoming Annual Report on Form 10-K.
Investor Verification Checklist
- Verify the final audited cash, cash equivalents, and marketable securities balance in the upcoming Form 10-K for the year ended December 31, 2025.
- Confirm whether the preliminary cash figure of $136.9 million changes after the completion of the year-end financial close.
- Review the full Form 10-K for detailed revenue, expense, and debt metrics not included in this 8-K.